← Azimuth Daily
Capturing data…
Capturing data…
WED, 4 NOV · 79 ITEMS
ABC News Australia, AFR, news.com.au · Australia
3 outletsAustralia's drug regulator, the Therapeutic Goods Administration, has approved a once-daily tablet version of — , the same GLP-1 drug already sold there as a weekly injection — for . The pill is Novo Nordisk's oral 25 mg semaglutide, a much higher dose than the older oral semaglutide sold for type 2 diabetes, formulated with an absorption enhancer so it can be swallowed rather than injected. Approval is a regulatory milestone, not a launch: the AFR reports the tablets are expected to go on sale in Australia before Christmas 2026, with pricing and supply still to be settled.
The core claim is a regulatory decision, and regulatory approvals are documented facts recorded on the 's Australian Register of Therapeutic Goods, so the reporting sits close to a primary source. Details beyond the approval itself — timing of retail availability, price, whether stock will be limited — come from company statements relayed by outlets like the AFR and are less firm than the approval decision.
Genuinely new: the coverage is dated 3 November 2026 and describes a fresh regulatory clearance, with no recirculated material involved.
We covered a related step in August 2026, when a once-daily pill for diabetes that also aids weight loss — oral semaglutide at a lower dose — reached UK pharmacies, part of the same shift of GLP-1 drugs from injections to tablets.